CGEN stock forecast, quote, news & analysis
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy... Show more
Why Compugen (CGEN) Stock Is Down -13% in the Last 30 Days
Key Takeaways
- Compugen shares declined roughly 13% over the past 30 days, moving from about $2.31 to approximately $2.01 as of early November 2026.
- The pullback extended a broader slide, with the stock down roughly 15% over the last quarter from its early-August levels near $2.38.
- Compugen remains a clinical-stage cancer immunotherapy company built around its AI-powered Unigen computational discovery platform and a pipeline spanning COM701, rilvegostomig, and GS-0321.
- A key near-term catalyst gap is a factor: the MAIA-ovarian interim analysis for COM701 is not expected until the first quarter of 2027.
- Third-quarter 2026 financial results are scheduled for release on November 9, 2026.
- Investors can find more detail on the company's Price Targets, Earnings, and Forecast on additional pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are approaching opportunities across the market.
Compugen (CGEN) Company Overview and Market Position
Compugen Ltd. is a clinical-stage cancer immunotherapy company headquartered in Holon, Israel, with shares listed on both Nasdaq and the Tel Aviv Stock Exchange. The company distinguishes itself through Unigen, an AI/ML-powered computational platform used to identify novel drug targets and develop immuno-oncology therapeutics. Its pipeline is anchored by COM701, a potential first-in-class anti-PVRIG antibody being evaluated in the MAIA-ovarian adaptive platform trial; rilvegostomig, a PD-1/TIGIT bispecific antibody developed under an exclusive license with AstraZeneca; and GS-0321, a potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead. The collaborations with AstraZeneca and Gilead together represent up to approximately $1 billion in potential milestone payments plus royalties, and the company has reported a cash runway expected to fund operations into 2029.
Compugen (CGEN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Compugen shares moved from a closing level of approximately $2.31 on October 5, 2026, to about $2.01 by early November 2026, a decline of roughly 13%. The move was not a straight line: the stock drifted lower through much of October, reached an intraday low area near $1.87 in late October, and then recovered modestly into the $2.00 range heading into November.
Looking at the broader quarter, the stock began the period near $2.38 in early August, climbed to an intraday peak around $2.87 in late August, and then gave back those gains through September and October. The result is a decline of roughly 15% from early-August levels, reflecting a period of optimism around the pipeline followed by profit-taking and a re-rating lower.
What Drove CGEN Stock Price in the Last 30 Days
The 30-day decline coincided with a relatively quiet stretch of clinical catalysts. Compugen's most significant upcoming data point, the MAIA-ovarian interim analysis for COM701, is not anticipated until the first quarter of 2027, leaving the stock without a near-term binary catalyst to support momentum. The company hosted a virtual KOL event on COM701 and the Unigen platform in early October and participated in an AI-based drug discovery conference, but these updates did not reverse the selling pressure.
Technical positioning also played a role. The stock traded below its 200-day moving average, which sat near $2.30 during the period, and hovered just above its prior post-earnings lows. Broader risk-off sentiment toward small-cap, clinical-stage biotechnology names contributed to the pressure, as investors appeared to await more concrete evidence of pipeline progress. The partial recovery in late October and early November came alongside the company's announcement of upcoming investor conference participation and its scheduled third-quarter earnings release.
What Drove CGEN Stock Performance Over the Last Quarter
The quarterly trend reflects a shift from momentum to caution. Compugen shares rallied sharply in late August, rising from the low-$2 range to roughly $2.87 on optimism surrounding AstraZeneca's expanding Phase 3 program for rilvegostomig and the broader potential of the COM701 franchise. That advance was followed by a steady retreat as investors digested the longer timeline to the MAIA-ovarian interim readout and the absence of near-term clinical data.
Sentiment was further shaped by the company's financial profile as a clinical-stage developer: revenue remains modest and dependent on partner milestones, while the company funds its pipeline through a cash balance reported at approximately $125.3 million at the end of June 2026. With the next major internal catalyst pushed to 2027, the stock gave back its summer gains and settled into a lower trading range.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies from a broader ecosystem of hundreds of AI-driven bots that trade across thousands of tickers. Rather than listing every available bot, the section highlights the top-performing and most relevant strategies, helping users identify approaches that are currently generating attention. The bots vary widely in strategy, timeframe, and performance metrics, from shorter-term tactical models to longer-horizon approaches. Investors and traders can use the page to explore how AI systems are navigating market conditions and to evaluate strategies that align with their own objectives. Visit Trending AI Robots to browse the latest curated strategies.
CGEN Stock Forecast Drivers: What Investors Should Watch Next
Several factors will likely shape Compugen's stock in the months ahead. First, the company's third-quarter 2026 results, scheduled for November 9, 2026, will offer updates on cash position, spending discipline, and program timelines. Second, the MAIA-ovarian interim analysis for COM701, expected in the first quarter of 2027, represents the most significant upcoming data catalyst. Third, AstraZeneca's continued advancement of rilvegostomig across multiple Phase 3 trials could influence the value of Compugen's royalty and milestone economics. Fourth, progress in Gilead's GS-0321 Phase 1 program and any timeline clarity around data disclosure may affect sentiment. Finally, broader market conditions for small-cap biotechnology and the pace of clinical enrollment remain important external variables for investors to monitor.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for CGEN turns positive, indicating new upward trend
CGEN saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 69 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGEN's RSI Oscillator exited the oversold zone, 35 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CGEN just turned positive on October 28, 2026. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +11.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 187 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for CGEN moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CGEN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CGEN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.092) is normal, around the industry mean (3.498). P/E Ratio (5.158) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drug and diagnostics
Industry Biotechnology